Floatz logo

ETOPOSIDE

Familial Erythrophagocytic Lymphohistiocytosis

Beijing Tongren HospitalSmall moleculePhase 4 / ApprovedActive
BBB
73/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
58/ 100
Competitive Position
95/ 100

Competitive context

20 Active assets in the Familial Erythrophagocytic Lymphohistiocytosis cohort.

Asset / SponsorPhaseRating
PEGASPARGASE
Beijing Tongren Hospital
Phase 4BB
Inno-206
The First Affiliated Hospital of Soochow University
Phase 4BB
CIS-DIAMMINEDICHLOROPLATINUM II
Zhengzhou University
Phase 4BB
Zanubrutinib
The First Affiliated Hospital of Soochow University
Phase 4BB
PEGASPARGASE
Zhengzhou University
Phase 4BB

View all 33 →

Same molecule, other indications

ETOPOSIDE is also rated in:

acute megakaryoblastic leukemiaDormant
BBB
Indicative ·
79 / 100
View asset →
acute monocytic leukemiaDormant
BBB
Indicative ·
79 / 100
View asset →
acute myeloblastic leukemia with maturationDormant
BBB
Indicative ·
79 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →